Efficacy and Safety of Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Immunoglobulin D Multiple Myeloma.

导出 LinkOut

翻译打印收藏纠错

第一作者： Wei,Chen

第一单位： Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China; Blood Diseases Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China; Jiangsu Key Laboratory of Bone Marrow Stem Cells, Xuzhou, Jiangsu, China.

作者： Wei,Chen ^[1] ; Ying,Wang ^[1] ; Kunming,Qi ^[1] ; Ming,Shi ^[2] ; Jiang,Cao ^[1] ; Rahul,Bhansali ^[3] ; Xue,Wang ^[1] ; Yang,Liu ^[1] ; Hujun,Li ^[1] ; Huanxin,Zhang ^[1] ; Zhiling,Yan ^[1] ; Wei,Sang ^[1] ; Hai,Cheng ^[1] ; Feng,Zhu ^[1] ; Haiying,Sun ^[1] ; Depeng,Li ^[1] ; Guangjun,Jing ^[4] ; Junnian,Zheng ^[5] ; Zhenyu,Li ^[6] ; Kailin,Xu ^[7]

作者单位： Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China; Blood Diseases Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China; Jiangsu Key Laboratory of Bone Marrow Stem Cells, Xuzhou, Jiangsu, China. ^[1] Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China; Cacer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China. ^[2] Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania. ^[3] iCARTAB Biomedical Co Ltd, Suzhou, Jiangsu, China. ^[4] Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China; Cacer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China. Electronic address: jnzheng@xzhmu.edu.cn. ^[5] Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China; Blood Diseases Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China; Jiangsu Key Laboratory of Bone Marrow Stem Cells, Xuzhou, Jiangsu, China. Electronic address: lizhenyumd@163.com. ^[6] Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China; Blood Diseases Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China; Jiangsu Key Laboratory of Bone Marrow Stem Cells, Xuzhou, Jiangsu, China. Electronic address: lihmd@163.com. ^[7]

关键词 B-cell maturation antigen Chimeric antigen receptor T cells Immunoglobulin D Multiple myeloma Relapsed/refractory

主题词人类(Humans);免疫球蛋白D(Immunoglobulin D);免疫疗法, 过继(Immunotherapy, Adoptive);多发性骨髓瘤(Multiple Myeloma)

DOI 10.1016/j.jtct.2020.12.017

PMID 33781540

发布时间 2022-05-31

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Transplantation and cellular therapy

2021年27卷3期

273.e1-273.e5页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Efficacy and Safety of Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Immunoglobulin D Multiple Myeloma.

Transplantation and cellular therapy

相似文献

Transplantation and cellular therapy

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Efficacy and Safety of Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Immunoglobulin D Multiple Myeloma.

Transplantation and cellular therapy

相似文献

Transplantation and cellular therapy

相关期刊

检索历史清除